Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company specializing in the research, development, and commercialization of innovative products for oncology. The company focuses on creating next-generation theranostic (therapy and diagnostic) agents, particularly using its proprietary SAR Technology Platform, which leverages copper isotopes to enhance both imaging and therapeutic characteristics of radiopharmaceuticals for cancer treatment. Clarity’s key product candidates, such as SARTATE, SAR-Bombesin, and SAR-bisPSMA, target specific cancer receptors, enabling precise diagnosis, staging, and treatment of cancers including those expressing somatostatin receptor 2, gastrin-releasing peptide receptor, and prostate-specific membrane antigen. Operating primarily in Australia and the United States, Clarity Pharmaceuticals plays a significant role within the healthcare and biotechnology sectors by addressing unmet needs in paediatric and adult oncology. Its mission is to improve treatment outcomes for cancer patients and advance the radiopharmaceutical industry through innovation and clinical progress.
